BeOne Medicines (ONC) Other Non-Current Liabilities (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Other Non-Current Liabilities of $82.0 million for Q1 2026, up 24.87% year-over-year from $65.6 million in Q1 2025, and up 2.13% quarter-over-quarter from $80.2 million in Q4 2025.
BeOne Medicines (ONC) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Other Non-Current Liabilities for 12 consecutive years, with $82.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 24.87% year-over-year to $82.0 million; the TTM figure through Mar 2026 stood at $82.0 million (up 24.87% YoY), while the FY2025 annual figure was $80.2 million, up 20.24% from the prior year.
- Other Non-Current Liabilities improved to $82.0 million in Q1 2026 per ONC's latest filing, from $80.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $180.5 million in Q4 2022 and bottomed at $42.0 million in Q3 2023.
- Historically, Other Non-Current Liabilities has averaged $63.5 million across 5 years, with a median of $51.5 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 232.77% — and 2023, when it slumped 71.85%.
- BeOne Medicines' Other Non-Current Liabilities stood at $180.5 million in 2022, then plunged by 71.85% to $50.8 million in 2023, then surged by 31.34% to $66.7 million in 2024, then climbed by 20.24% to $80.2 million in 2025, then rose by 2.13% to $82.0 million in 2026.
- Business Quant data shows ONC's Other Non-Current Liabilities at $82.0 million in Q1 2026, $80.2 million in Q4 2025, and $64.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.64 Mn |
| Mar 31, 2026 | 81.95 Mn |
| Dec 31, 2025 | 80.25 Mn |
| Sep 30, 2025 | 64.06 Mn |
| Jun 30, 2025 | 63.08 Mn |
| Mar 31, 2025 | 65.63 Mn |
| Dec 31, 2024 | 66.74 Mn |
| Sep 30, 2024 | 50.57 Mn |
| Jun 30, 2024 | 51.53 Mn |
| Mar 31, 2024 | 48.90 Mn |
| Dec 31, 2023 | 50.81 Mn |
| Sep 30, 2023 | 41.99 Mn |
| Jun 30, 2023 | 43.12 Mn |
| Mar 31, 2023 | 45.62 Mn |
| Dec 31, 2022 | 180.47 Mn |
| Sep 30, 2022 | 45.17 Mn |
| Jun 30, 2022 | 48.43 Mn |
| Mar 31, 2022 | 51.83 Mn |
| Dec 31, 2021 | 54.23 Mn |
| Sep 30, 2021 | 54.61 Mn |